ARA-GUANOSINE
Advanced Cancer
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
93 Active assets in the Advanced Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BB |
Irinotecan MOMA Therapeutics | Phase 3 | BB |
Osimertinib NING LI | Phase 4 | BB |
Ipilimumab 7 Hills Pharma, LLC | Phase 2 | BB |
View all 50 →
Same molecule, other indications
ARA-GUANOSINE is also rated in:
Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT BenefitDormant
CCC
Indicative ·
52 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →